



**For Immediate Release**

**October 20, 2017**

## **VALENS GROWORKS ANNOUNCES EXERCISE OF WARRANTS**

**Vancouver, B.C., October 20, 2017 – Valens GroWorks Corp. (CSE: VGW)** (the “Company” or “Valens”) is pleased to announce the exercise of 322,221 warrants at a price of \$0.75 per share, resulting in the issue of 322,221 common shares (“Shares”) of the Company. This provides \$41,666 cash added to the Company’s treasury, and a \$200,000 reduction in payables. Insider participation represents \$200,000 of the total proceeds of \$241,666.

These Shares are being issued pursuant to the terms of the Warrant Certificates attached to the Private Placement closed by the Company and filed with the Canadian Securities Exchange (“CSE”) on October 23, 2015.

Following issuance of these Shares, Valens will have 60,699,609 common shares issued and outstanding. No commissions or placement fees have been paid related to the proceeds from this warrant exercise. Proceeds are earmarked for general corporate purposes.

### **About Valens GroWorks Corp.**

Valens GroWorks Corp. is a CSE-listed biotechnology company with an aggressive buildout strategy in progress. The Company seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious seed-to-sale and farm-to-pharma objectives. The Company provides management, consulting, testing and support services to domestic and international licensees, as well as financial support to fully-licensed third-party operations.

The Company operates through two wholly-owned subsidiaries based in the Okanagan Valley of British Columbia: Valens Agritech Ltd. (“VAL”) holds a Health Canada Dealer’s License and is commencing cannabis production and further expansion, and Supra THC Services Inc. (“Supra”), a Health Canada licensed cannabis testing lab providing sector-leading analytical and proprietary services to Licensed Producers and ACMPR patients.

Both subsidiaries are involved in a collaborative research partnership with BC-based universities UBC Okanagan and Thompson Rivers to explore the vast range of bioproducts that can be made from cannabis plant materials. Supra, in collaboration with Thermo Fisher Scientific (Mississauga) Inc., is developing a “*Centre of Excellence in Plant Based Medicine Analytics*” at the Company’s 17,000 square foot facility located on two acres in Kelowna. For more information, please visit <http://valensgroworks.com>, <http://www.valensagritech.com> and <http://www.suprathc.ca>.

**On behalf of the Board of Directors,  
VALENS GROWORKS CORP.**

(signed) “Rob van Santen”  
Chief Financial Officer

**For further information, please contact:**

---

Valens GroWorks Corp.  
14th Floor, 1040 West Georgia Street,  
Vancouver, British Columbia, Canada V6E 4H1  
T. 604.608.1999 F. 788.379.9990  
[www.valensgroworks.com](http://www.valensgroworks.com)

Greg Patchell  
Telephone: +1.250.860.8634

#### Notice regarding Forward Looking Statements

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.